Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Fibrosis, Oncology, and Regenerative Medicine.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for TGFB3 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TGFB3 Active Form Recombinant Protein. High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). Latency-free active domain. | View TGFB3 Products |
| Isoform Panel | TGFB1 / TGFB2 / TGFB3 Protein Set. For selectivity screening. Human/Mouse/Cyno orthologs available. | View TGFB1 Products |
| Gene Delivery | TGFB3 Promise-ORF / Lentivirus. Full-length ORF including LAP sequence for latency studies. Ready for stable cell line generation. | View TGFB3 Products |
| Receptor System | TGFBR1 (ALK5) & TGFBR2 Lentivirus Premade Particles. For constructing SMAD reporter cell lines. Native conformation preserved. | View TGFBR1 Products |
| Benchmark Ab | Anti-TGFB3 Benchmark Antibody. Recombinant positive control for total TGF Beta detection. | View TGFB3 Products |
| Validator | TGFB3 siRNA Set. For knockdown verification and specificity confirmation. | View TGFB3 Products |
| Signaling Node | SMAD2 / SMAD3 Recombinant Proteins. Downstream effectors for phosphorylation assays. | View SMAD2 Products |
| Related Target A | TGFB1. Isoform specificity profiling and pan-TGFB inhibitor screening. | View TGFB1 Products |
| Related Target B | TGFB2. Toxicity mitigation and selectivity profiling. | View TGFB2 Products |
| Related Target C | TGFBR2. Essential co-receptor for TGFB3 signaling. Critical for heterodimer binding assays. | View TGFBR2 Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform Selectivity (TGFB3 vs TGFB1/TGFB2) | Complete panel of human TGFB isoforms available with >95% purity and verified theoretical MW. Sequence verified by mass spec. Strict endotoxin control (<0.1EU/ug) for sensitive cell assays. |
| Active Dimer Conformation | HEK293 Expressed (Native Glycosylation and folding) for strict structural integrity. |
| Latency/Activation State Screening | TGFB3 LAP complex protein and active form available separately. For mechanistic antibody development targeting prodomain cleavage. |
| Receptor Heterodimer Engagement | TGFBR1/TGFBR2 co-transfection lentivirus system. Cell-based assays preserve physiological conformation vs. purified ECD proteins. |
| Cross-species Translation (Cyno/Mouse) | Human/Mouse/Cynomolgus ortholog proteins with matched QC specs. Sequence alignment verified for epitope conservation. |
| Off-target Safety (BMP/GDF Family) | Extended TGF Beta superfamily protein panel (BMP2, BMP4, GDF15) for counter-screening. High specificity validation reagents. |
| Lack of Positive/Negative Controls | Clinical Benchmark Antibodies and validated siRNA included for direct affinity comparison and specificity checks in cell-based assays. |
| False Positives in Cell Assays | Validated siRNA included for specificity checks; endotoxin-controlled proteins avoid TLR4-mediated activation. |
Live TGFB3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials
- ➤ Latest Fibrosis & Mechanism Research
- ➤ Latest Resistance Research
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
The race for TGFB3 therapeutics is intensifying, with major players shifting focus from broad-spectrum pan-TGFB inhibitors to isoform-selective neutralizing antibodies, bispecifics (e.g., PD-L1/TGFB trap), and targeted modalities. TGF-beta signaling plays a dual role in tumor suppression and promotion, as well as driving fibrosis and immunosuppression in the tumor microenvironment (TME). Historically, pan-TGFB inhibitors like Fresolimumab encountered dose-limiting toxicities (cardiovascular, cutaneous) due to inhibition of TGFB1's homeostatic functions. The next wave of R&D aims at optimal therapeutic windows: TGFB3-selective modulation for scarless wound healing and selective fibrosis regression without immunosuppression, while in oncology, combined TGFB blockade with immune checkpoint inhibitors seeks to overcome the "immune excluded" phenotype. As first-generation therapies reach the clinic, precision targeting of TGFB3 is critical.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (Isoform-Selective) | Novartis, Sanofi; Pharmaceuticals exploring scarless healing | Fibrosis, Solid Tumors; Dermal Scarring | Isoform Selectivity Assay (Need panel of high-purity TGFB1/2/3) |
| Bispecific (PD-L1/TGFB trap) | Merck KGaA, Hengrui | Advanced Solid Tumors | Functional Neutralization (Need active dimeric antigens) |
| Small Molecule (Receptor) | Eli Lilly, Pfizer | Oncology | Receptor Binding Assays (Need high-purity ligand and receptor proteins) |
| Antisense Oligonucleotides | Specialty biotech firms | Ocular Fibrosis, Capsular Contracture | Knockdown Validation (Need validated siRNA controls for specificity) |
| Recombinant Protein (Augmentation) | Regenerative medicine companies | Scarless Wound Healing, Dental | Activity Assay (Need high-purity active TGFB3 with native disulfide bonding) |
| Trap/Decoy Receptors | Oncology biotechs | Solid Tumors (TME modulation) | Receptor Binding Assay (Need TGFBR1/TGFBR2 heterodimer cell lines) |